Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Biomed Mater Res B Appl Biomater ; 108(5): 2227-2237, 2020 07.
Artículo en Inglés | MEDLINE | ID: mdl-31970926

RESUMEN

The use of chitosan as a pharmaceutical excipient in the ocular field is already established. Nevertheless, some aspects related to its ocular administration, such as sterilization and excipient's pharmacokinetics, remain unclear. So, in this study, we evaluated those two relevant aspects, related to chitosan administration in eye. We used chitosan-based ocular inserts (CI) as formulation model. CI were produced by solvent/casting method and sterilized by saturated steam. Sterilization was confirmed by direct inoculation of inserts in suitable microbiological growth media. Physicochemical characterization of inserts before and after sterilization was performed. Results suggested that, although steam sterilization changed the arrangement of the matrix, the heat and the humidity did not modify the structure of the main polymeric chain. Pharmacokinetics of CI radiolabeled with technetium-99m (99m Tc) was assessed by scintigraphic images and ex vivo biodistribution study, after ocular administration in male Wistar rats. Scintigraphic and images analysis and ex vivo biodistribution study showed that the insert remained mainly in the eye until 6 hr after administration and its degradation products began to migrate to the abdominal cavity after 18 hr. Together, these data represent an important step forward the manufacturing and the clinical application of CI in the ophthalmic field.


Asunto(s)
Quitosano/química , Portadores de Fármacos/química , Excipientes/química , Administración Oftálmica , Animales , Quitosano/administración & dosificación , Quitosano/farmacocinética , Humanos , Masculino , Ratas , Esterilización , Relación Estructura-Actividad , Distribución Tisular
2.
Eur J Pharm Sci ; 111: 57-64, 2018 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-28958891

RESUMEN

Mesalamine (5-ASA) consists of the first-line therapy for the treatment of ulcerative colitis; however, it has low bioavailability, can cause several systemic adverse events, and has low treatment adherence due to the inconvenient dosing scheme. In this work, a new drug delivery system consisting of chondroitin sulfate linked to 5-ASA was synthesized using a carbodiimide as conjugating agent. The system was characterized by spectroscopic techniques (UV, ATR-FTIR, XRD, and NMR 1H) and thermal analysis (TG/DTG and DSC), suggesting the conjugation between the drug and the polymer. The in vitro release and the corresponding kinetics were also evaluated, revealing that approximately 40% of the drug linked was released at pH9 for up to 50h, following Higuchi's model. The conjugate did not show cytotoxicity for the human monocytic cell line at the doses tested, and an in vivo biodistribution study showed that the conjugate remained in the lower GIT for up to 8h with no uptake in the upper GIT. These data corroborate with the radiation found per segment of GIT and in blood. For this last test the conjugate was radiolabeled with Technetium-99m to allow the scintigraphy evaluation and radiation quantification. In conclusion, the polymeric conjugate was successfully synthesized and demonstrated a mucoadhesiveness on the colon as desired, thus supporting its potential use in the treatment of ulcerative colitis.


Asunto(s)
Sulfatos de Condroitina/química , Portadores de Fármacos/química , Mucosa Intestinal/metabolismo , Mesalamina/administración & dosificación , Profármacos/administración & dosificación , Disponibilidad Biológica , Línea Celular , Colitis Ulcerosa/tratamiento farmacológico , Preparaciones de Acción Retardada , Composición de Medicamentos , Humanos , Mesalamina/farmacocinética , Mesalamina/farmacología , Monocitos/efectos de los fármacos , Monocitos/inmunología , Profármacos/farmacocinética , Profármacos/farmacología , Distribución Tisular , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...